This review evaluated the effectiveness of cyclooxygenase-2 (COX-2) selective non-steroidal anti-inflammatory drugs (NSAIDS) for osteoarthritis (OA) and rheumatoid arthritis (RA) patients. The authors concluded that COX-2 selective NSAIDs were similar to non-selective NSAIDs for the symptomatic relief of these conditions and provided superior GI tolerability. This was a well-conducted review and the authors' conclusions were likely to be reliable.
Study selection
Randomised controlled trials (RCTs) with a treatment duration two weeks or more that included patients with RA or OA treated with the COX-2 selective NSAIDS celecoxib, rofecoxib, meloxicam, etodolac, etoricoxib, valdecoxib and lumiracoxib (with or without concomitant medication) were eligible for inclusion in the review.
Eligible comparators were placebo, non-selective NSAIDS or direct comparisons between COX-2 selective NSAIDS. Trials of licensed and supra-licensed doses were considered. Dose-finding studies of COX-2 selective NSAIDS without comparison, studies of sub-therapeutic doses and abstracts were excluded. The included comparator drugs were naproxen, piroxicam, diclofenac, indomethacin, tenoxicam, ibuprofen, nabumetone and nimesulide. The majority of included patients had OA. The mean age range across all studies ranged from 48 to 83 years. Trial duration was generally three months or less.
Outcomes selected for data synthesis were: efficacy (defined in all trials as pain assessment using the VAS or WOMAC subscale); global assessment of response to therapy or disease status and withdrawals due to lack of efficacy (ACR-20 was used additionally in RA trials); tolerability (defined in all trials as total and gastro-intestinal (GI) specific events and withdrawals for any reason); and safety (defined in all trials as endoscopically confirmed GI ulcers, complicated upper gastro-intestinal (UGI) events, or these combined with symptomatic GI ulcers, myocardial infarction (MI) and serious cardiovascular thrombotic events).
Two independent reviewers selected studies for inclusion. Disagreements that could not be resolved by discussion were referred to a third reviewer.
Assessment of study quality
The JADAD scale was used to provide a composite score (5 representing good quality) for randomisation method, allocation concealment, blinding, use of ITT analysis, and reporting of loss to follow up. Study quality was assessed by one reviewer and checked by a second. Disagreements that could not be resolved by discussion were referred to a third reviewer. Data were extracted by one reviewer and checked independently by a second reviewer; disagreements were resolved by discussion. Raw data or available summary measures (for example, mean differences for pain scores and relative risk (RR) for adverse events) with standard deviations, 95% confidence intervals (CIs) and p-values were extracted. The intention to treat (ITT) population was used where possible.
Data extraction

Methods of synthesis
Data were synthesised in meta-analyses. Relative risks (RRs) were pooled using the Mantel-Haenszel method. Mean differences were variance-weighted to provide the weighted mean difference (WMD). Heterogeneity was assessed using meta-regression, the Χ 2 test. Subgroup analyses were carried out to explore the impact of aspirin use, steroid use, prior GI history, and Helicobacter pylori status. Where heterogeneity was statistically significant (p<0.10), the DerSimonian Laird random effects model was used. Data were imputed where trials reported only a mean variance at baseline and follow up.
Results of the review
One hundred and thirty-one RCTs were included in the review. There were discrepancies between the tables and text that indicated lower doses than those reported below for meloxicam (3.75 mg/day), celecoxib (80 mg/day), etoricoxib (5 mg/day), and valdecoxib (1 mg/day). Statements on study quality were not supported by average scores in all cases.
Etodolac
Only two of 29 RCTs (n=5,775) were considered to be good quality. Etolodac (600 mg/day to 1,000 mg/day) was found to be equally effective and demonstrated equivalent or superior GI tolerability when compared to other non-selective NSAIDs. Significantly fewer clinical UGI events were reported, RR 0.32 (95% CI: 0.15, 0.71). No MIs were reported.
Meloxicam
In 16 RCTs (n=22,886), overall trial quality was considered to be moderate (mean score 3). Meloxicam (range 7.5 mg/day to 22.5 mg/day) was found to be of inferior or equivalent efficacy and demonstrated superior GI tolerability when compared to other non-selective NSAIDs. Significantly fewer clinical UGI events were reported, RR 0.53 (95% CI: 0.29, 0.97). There was insufficient data to assess MI risk.
Celecoxib
In 37 RCTs (median sample size 655 patients), overall trial quality was considered good, but withdrawals were high (20 per cent to 50 per cent). Celecoxib (200 mg/day to 800 mg/day) was found to be equally effective and of superior GI tolerability when compared to other non-selective NSAIDs. Significantly fewer clinical UGI events, RR 0.55 (95% CI: 0.40, 0.76) and complicated UGI events, RR 0.57 (95% CI: 0.35, 0.95) were reported. There was a significantly higher risk of MI, RR 1.77 (95% CI: 1.00, 3.11). The results of sub-group analyses were inconclusive.
Rofecoxib
In 23 RCTs (n=26,406), 21 trials were considered to be of good quality. Rofecoxib (12.5 mg/day to 50 mg/day) was found to be equally effective and had superior GI tolerability when compared with other non-selective NSAIDs. Significantly fewer clinical UGI events RR 0.43 (95% CI: 0.32, 0.57) and complicated UGI events, RR 0.40 (95% CI: 0.23, 0.70) were reported. There was a significantly higher risk of MI, RR 2.92 (95% CI: 1.36, 6.28). The results of subgroup analyses were inconclusive.
Etoricoxib
In seven RCTs (n=approximately 3,461), overall trial quality was judged to be moderate to good (median score 4). Etoricoxib (60 mg/day to 120 mg/day) was equally effective and of equivalent of superior GI tolerability when compared to other non-selective NSAIDs.
Valdecoxib
In 11 RCTs (n=9,293), overall trial quality was considered to be good. Valdecoxib (10 mg/day 80 mg/day) was equally 
Cost information
In analyses using ibuprofen or diclofenac as the comparators, all COX-2 products were associated with higher costs and small increases in effectiveness in relation to quality adjusted life years (QALYs). The magnitude of incremental costs and effects, and corresponding cost-effectiveness ratios varied considerably across all COX-2 selective NSAIDs and depended on the risk status of patients. When a proton pump inhibitor (PPI) was incorporated into the analyses, COX-2 products became less cost-effective. Full details of the economic evaluation are given in the report.
